• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Criminal or bystander: imatinib and second primary malignancy in GIST patients.

作者信息

Kanda Tatsuo

机构信息

Sanjo General Hospital, Sanjo City, Niigata, Japan.

出版信息

Chin J Cancer Res. 2013 Oct;25(5):490-2. doi: 10.3978/j.issn.1000-9604.2013.10.15.

DOI:10.3978/j.issn.1000-9604.2013.10.15
PMID:24255570
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3828432/
Abstract
摘要

相似文献

1
Criminal or bystander: imatinib and second primary malignancy in GIST patients.罪犯还是旁观者：伊马替尼与胃肠道间质瘤患者的第二原发性恶性肿瘤
Chin J Cancer Res. 2013 Oct;25(5):490-2. doi: 10.3978/j.issn.1000-9604.2013.10.15.
2
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.伊马替尼辅助治疗1年对Kit阳性局限性胃肠间质瘤手术切除后的预算影响
J Manag Care Pharm. 2010 Sep;16(7):482-91. doi: 10.18553/jmcp.2010.16.7.482.
3
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.荷兰胃肠道间质瘤（GIST）登记数据比较舒尼替尼与伊马替尼剂量递增在二线晚期非 KIT 外显子 9 突变 GIST 患者。
Target Oncol. 2022 Nov;17(6):627-634. doi: 10.1007/s11523-022-00926-6. Epub 2022 Nov 14.
4
Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review.术前伊马替尼治疗期间十二指肠 GIST 的戏剧性进展和出血：病例报告及复习。
World J Surg Oncol. 2010 Jun 2;8:47. doi: 10.1186/1477-7819-8-47.
5
Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis.胃肠间质瘤辅助伊马替尼治疗指南的依从性：一项多机构分析
J Gastrointest Surg. 2015 Jun;19(6):1022-8. doi: 10.1007/s11605-015-2782-7. Epub 2015 Mar 3.
6
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.伊马替尼治疗不可切除和/或转移性胃肠道间质瘤患者：系统评价与经济学评估
Health Technol Assess. 2005 Jul;9(25):1-142. doi: 10.3310/hta9250.
7
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.血清miR-518e-5p是继发性伊马替尼耐药胃肠道间质瘤的潜在生物标志物。
J Biosci. 2018 Dec;43(5):1015-1023.
8
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.管理 GIST 患者的进行性疾病：除继发获得性酪氨酸激酶抑制剂耐药以外需要考虑的因素。
Cancer Treat Rev. 2012 Aug;38(5):467-72. doi: 10.1016/j.ctrv.2011.10.001. Epub 2011 Oct 27.
9
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.初治及伊马替尼耐药胃肠道间质瘤中的新型V600E BRAF突变
Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.
10
Ripretinib for the treatment of advanced gastrointestinal stromal tumor.瑞派替尼用于治疗晚期胃肠道间质瘤。
Therap Adv Gastroenterol. 2021 Apr 15;14:17562848211008177. doi: 10.1177/17562848211008177. eCollection 2021.

引用本文的文献

1
Altered expression profile of micrornas in gastric stromal tumor.胃间质瘤中微小RNA的表达谱改变
J Huazhong Univ Sci Technolog Med Sci. 2015 Dec;35(6):842-850. doi: 10.1007/s11596-015-1516-0. Epub 2015 Dec 16.
2
Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.胃胃肠道间质瘤辅助甲磺酸伊马替尼治疗期间发生的异时性原发性肺癌：一例报告
Medicine (Baltimore). 2015 Sep;94(36):e1484. doi: 10.1097/MD.0000000000001484.
3
The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies.胃肠道间质瘤与第二原发性恶性肿瘤的发生
J Gastrointest Cancer. 2015 Dec;46(4):408-12. doi: 10.1007/s12029-015-9759-3.
4
Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.胃肠道间质瘤（GIST）患者的其他原发性恶性肿瘤：一项对260例患者的临床病理研究及分子分析与文献复习
Ann Surg Oncol. 2015 Aug;22(8):2633-9. doi: 10.1245/s10434-014-4332-z. Epub 2015 Jan 7.
5
microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.微小RNA-218通过PI3K/AKT途径提高胃肠道间质瘤对伊马替尼的敏感性。
Clin Exp Med. 2015 May;15(2):137-44. doi: 10.1007/s10238-014-0280-y. Epub 2014 Apr 5.
6
MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.微小RNA-218通过靶向KIT抑制胃肠道间质瘤细胞增殖和侵袭。
Tumour Biol. 2014 May;35(5):4209-17. doi: 10.1007/s13277-013-1551-z. Epub 2013 Dec 29.

本文引用的文献

1
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.甲磺酸伊马替尼引入前后的胃肠道间质瘤和第二原发性恶性肿瘤
Chin J Cancer Res. 2013 Oct;25(5):486-7. doi: 10.3978/j.issn.1000-9604.2013.10.13.
2
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.前瞻性观察性研究伊马替尼治疗晚期胃肠间质瘤的日本患者：长期随访和第二恶性肿瘤。
Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.
3
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.手术后胃肠道间质瘤复发风险：基于人群队列的汇总分析。
Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Epub 2011 Dec 6.
4
Co-existence of gastrointestinal stromal tumors with other primary neoplasms.胃肠道间质瘤与其他原发性肿瘤并存。
Hepatogastroenterology. 2011 May-Jun;58(107-108):824-30.
5
Occurrence of other tumors in patients with GIST.GIST 患者中的其他肿瘤发生情况。
Surg Oncol. 2010 Dec;19(4):e140-3. doi: 10.1016/j.suronc.2010.06.004. Epub 2010 Aug 2.
6
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.多原发恶性肿瘤患者的生存：783 例胃肠道间质瘤患者的研究。
Ann Oncol. 2010 Oct;21(10):2107-2111. doi: 10.1093/annonc/mdq078. Epub 2010 Mar 26.
7
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.比较两种剂量伊马替尼治疗不可切除或转移性胃肠道间质瘤的疗效：一项纳入 1640 例患者的荟萃分析。
J Clin Oncol. 2010 Mar 1;28(7):1247-53. doi: 10.1200/JCO.2009.24.2099. Epub 2010 Feb 1.
8
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.一项针对表达KIT的不可切除或转移性胃肠道间质瘤患者，比较标准剂量与高剂量甲磺酸伊马替尼的随机II期试验的长期结果。
J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.
9
Coexistence of gastrointestinal stromal tumors with other neoplasms.胃肠道间质瘤与其他肿瘤的共存。
J Gastroenterol. 2007 Aug;42(8):641-9. doi: 10.1007/s00535-007-2082-4. Epub 2007 Aug 24.
10
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.微小胃硬化性间质瘤（GIST小结节）在成人中很常见，且常表现为c-KIT基因突变。
Am J Surg Pathol. 2007 Jan;31(1):113-20. doi: 10.1097/01.pas.0000213307.05811.f0.